TrialThe oncologist2026

Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study.

Xiaojun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.